Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Legend Biotech

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo gets two new indications in Europe

Receives green light as lung and kidney cancer immunotherapy

EU flag

Boehringer’s Giotrif wins new NSCLC licence in Europe

Can now be marketed for advanced squamous cell carcinoma of the lung

- PMLiVE

J&J drops NGF blocker fulranumab

Says decision to return rights to Amgen based on “strategic portfolio prioritisation”

- PMLiVE

J&J launches collaborative innovation initiative

Aims to fuel evolution of new industry models

- PMLiVE

FDA clears Imbruvica as chemo alternative for first-line CLL

Johnson & Johnson/AbbVie's first-in-class drug now approved for all CLL patients

J&J’s portent of purity

The future of corporate structures is emerging before our eyes

National Institute for Health and Care Excellence NICE logo

NICE’s rejection of Imbruvica ‘reveals appraisal process flaws’

Leukaemia charity says the cost-effectiveness body can't cope with uncertainty

- PMLiVE

AstraZeneca wins EU approvals for Zurampic and Brilique

Its gout drug receives a licence and antiplatelet therapy gains a new indication

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

EU forms mHealth app working group

Tasks it with drafting guidelines for assessing the validity and reliability of the data collected

- PMLiVE

emotive eye healthcare app scoops mobile learning award

The Eye Education app was produced for Johnson & Johnson Vision Care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links